We also sequenced the polycomb complex repressor 2 (PRC2) components EZH2, SUZ12, and EED, as frequently co-altered with RAS pathway genes in other cancers [19] in 104 samples from our cohort, and found that 50% and 13.8% of RAS+ and RAS− cases, respectively had concomitant PRC2 alteration (p < 0.0001, Supplementary Fig. 1E). The gene discussed is EZH2; the disease is cancer.